About CHINA ASSET MANAGEMENT (HK) CHINAAMC HANG SENG BIOTECH ETF CNY

83069 invests in stocks. The fund's major sectors are Health Technology, with 88.90% stocks, and Consumer Non-Durables, with 2.67% of the basket. The assets are mostly located in the Asia region.

83069 top holdings are Innovent Biologics, Inc. and Wuxi Biologics (Cayman) Inc., occupying 11.01% and 9.43% of the portfolio correspondingly.

83069 last dividends amounted to 0.06 CNY. The year before, the issuer paid 0.03 CNY in dividends, which shows a 51.20% increase.

83069 assets under management is ‪698.36 M‬ CNY. It's risen 14.10% over the last month.

83069 fund flows account for ‪−237.41 M‬ CNY (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.

83069 shares are issued by CITIC Securities Co., Ltd. under the brand ChinaAMC. The ETF was launched on Mar 18, 2021, and its management style is Passive.

83069 expense ratio is 0.71% meaning you'd have to pay 0.71% of your investment to help manage the fund.

83069 follows the Hang Seng Biotech Index - HKD - Benchmark TR Net. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.

83069 invests in stocks.

83069 price has fallen by −2.20% over the last month, and its yearly performance shows a 99.31% increase. See more dynamics on 83069 price chart.
NAV returns, another gauge of an ETF dynamics, have risen by 17.73% over the last month, showed a 47.27% increase in three-month performance and has increased by 104.95% in a year.